ePT--the Electronic Newsletter of Pharmaceutical Technology, May 5, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, May 5, 2011
News
FDA to Study Online Drug Marketing
By Angie Drakulich
FDA is collecting public comments on a series of studies that the agency plans to conduct on online direct-to-consumer promotion of prescription drug products, according to an announcement in the Federal Register.
Teva Snatches Cephalon from Valeant
By Rich Whitworth
Israel-based Teva Industries seals deal to acquire Cephalon for $6.8 billion.
PhRMA Urges Congress to Reauthorize Legislation for Pediatric Drugs
By Patricia Van Arnum
PhRMA Urges Congress to Reauthorize Legislation for Pediatric Drugs.
Excipient-Certification Standards Presented for Comment
By Erik Greb
The IPEC is soliciting public comment about a draft plan for the independent certification of manufacturers and suppliers of pharmaceutical excipients.
Federal Appeals Court Lifts Ban on Funding for Embryonic Stem Cell Research
By Amy Ritter
A federal appeals court has lifted a ban on federal funding for embryonic stem cell research.
Week of May 5, 2011: Company and People Notes: Velesco partners with Vindonwestech; NeurogesX announces retirement of CEO Anthony DiTonno; and More.
Velesco partners with Vindonwestech; NeurogesX announces retirement of CEO Anthony DiTonno; and More.
Regulatory Roundup: FDA Calling on Industry to Provide Feedback on Existing Regulations
FDA Calling on Industry to Provide Feedback on Existing Regulations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Click here